1: Sullivan GM, Parsey RV, Kumar JS, Arango V, Kassir SA, Huang YY, Simpson NR, Van Heertum RL, Mann JJ. PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: is the target of sufficient density? Nucl Med Biol. 2007 May;34(4):353-61. PubMed PMID: 17499724; PubMed Central PMCID: PMC1933490.
2: Li YW, Fitzgerald L, Wong H, Lelas S, Zhang G, Lindner MD, Wallace T, McElroy J, Lodge NJ, Gilligan P, Zaczek R. The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists. CNS Drug Rev. 2005 Spring;11(1):21-52. Review. PubMed PMID: 15867951.
3: Li YW, Hill G, Wong H, Kelly N, Ward K, Pierdomenico M, Ren S, Gilligan P, Grossman S, Trainor G, Taub R, McElroy J, Zazcek R. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. J Pharmacol Exp Ther. 2003 Apr;305(1):86-96. PubMed PMID: 12649356.
4: Lelas S, Zeller KL, Ward KA, McElroy JF. The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats. Psychopharmacology (Berl). 2003 Apr;166(4):408-15. PubMed PMID: 12590355.
5: McElroy JF, Ward KA, Zeller KL, Jones KW, Gilligan PJ, He L, Lelas S. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Psychopharmacology (Berl). 2002 Dec;165(1):86-92. PubMed PMID: 12474122.
6: Maciag CM, Dent G, Gilligan P, He L, Dowling K, Ko T, Levine S, Smith MA. Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation. Neuropsychopharmacology. 2002 May;26(5):574-82. PubMed PMID: 11927182.